StockData

Neuphoria Therapeutics vs Ovid Therapeutics

NEUP and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NEUP and OVID compare

Ovid Therapeutics scores higher on the StockData Score (10 against 5 for Neuphoria Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNEUPOVID
Size and price
Market cap–$434M
Share price$2.27$2.22
Change, 1 year−52.6%70.1%
Change, 5 years–−31.9%
Beta (5Y)0.821.34
Employees723
StockData Score
Total score510 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score02 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–274×
P/B–2.1×
Growth
Revenue growth (TTM)–−76.2%
Revenue growth, 5Y average–−10.5%
Profitability
Operating margin–−3687%
Net margin–−2179%
Return on equity−61.7%−26.0% (better)
Return on invested capital−273%−160% (better)
Financial health
Debt / equity0.000.00
Current ratio27.85 (better)12.39
Altman Z-score–9.41
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions36.8%75.3%
Held by insiders–13.6%
Insider net buying, 12 months$0 (better)−$29.3K
Short interest, % of float–10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.